Crispr dna targeting enzymes and systems
US-2024101990-A1 · Mar 28, 2024 · US
US10138468B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10138468-B2 |
| Application number | US-201615010389-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 29, 2016 |
| Priority date | Jul 29, 2013 |
| Publication date | Nov 27, 2018 |
| Grant date | Nov 27, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This application relates to a method for differentiating pluripotent stem cells (PSCs) into multi-competent renal precursor cells expressing Six2. These renal precursor cells are able to differentiate into fully functional and fully differentiated podocytes. Moreover this application relates to a method for differentiating human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) into defined renal precursor cells expressing Six2 and podocytes based on linked steps of chemically defined medium inductions.
Opening claim text (preview).
The invention claimed is: 1. A method for differentiating human or mouse pluripotent stem cells into renal precursor cells expressing SIX2, WT1 and SALL1, the method comprising the steps of: a) providing a monolayer of human or mouse pluripotent stem cells in a pluripotency medium, b) incubating the cells of step a) in an adherent culture for at least three days in a medium supplemented with 3-(3-amino-phenyl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione and recombinant bone morphogenic protein-4 (BMP4), and c) differentiating the cells of step b) in a serum-free medium supplemented with recombinant bone morphogenic protein-7 (BMP7) and retinoic acid, to produce renal precursor cells expressing SIX2, WT1 and SALL1. 2. The method of claim 1 , wherein the pluripotency medium of step a) is a serum-free medium supplemented with an inhibitor of the Rho-associated coiled-coil forming protein serine/threonine kinase family of protein kinases (ROCK kinase inhibitor). 3. The method of claim 2 , wherein the ROCK kinase inhibitor is selected from the group consisting of 1-(5-Isoquinolinesulfonyl) homopiperazine, N-Benzyl-2-(pyrimidin-4-ylamino) thiazole-4-carboxamide, and (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide dihydrochloride). 4. The method of claim 1 , wherein the medium of step b) is a serum free medium supplemented with insulin, transferrin and progesterone. 5. The method of claim 1 , wherein step a) comprises incubating the cells in the pluripotency medium for 18 hours to 30 hours. 6. The method of claim 1 , wherein step b) comprises incubating the cells in the medium for 3 to 4 days. 7. The method of claim 1 , wherein step c) comprises incubating the cells in the medium for 18 hours to 48 hours. 8. The method of claim 1 , wherein the pluripotent stem cell is an induced pluripotent stem cell. 9. The method claim 8 , wherein the induced pluripotent stem cell is obtained from a subject suffering from a renal disease. 10. A method for differentiating human or mouse pluripotent stem cells into renal precursor cells expressing SIX2, WT1 and SALL1, the method comprising the steps of: a) providing a monolayer of human or mouse pluripotent stem cells in a pluripotency medium, b) incubating the cells of step a) in an adherent culture for at least three days in a medium supplemented with 3-(3-amino-phenyl)-4-(1-methyl-1H-indo-1-3-yl)-pyrrole-2,5-dione and recombinant bone morphogenic protein-4 (BMP4), c) differentiating the cells of step b) in a serum-free medium supplemented with recombinant bone morphogenic protein-7 (BMP7) and retinoic acid, to produce renal precursor cells expressing SIX2, WT1 and SALL1, and d) incubating the renal precursor cells of step c) in a medium comprising retinoic acid and vitamin D3 to obtain proliferating podocytes. 11. The method of claim 10 , wherein the medium of step d) is supplemented with 10-200 nM vitamin D3.
Kinases (EC 2.7.) · CPC title
from artificially induced pluripotent stem cells · CPC title
Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title
of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] · CPC title
Insulin-transferrin; Insulin-transferrin-selenium · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.